(NASDAQ: MTVA) Metavia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Metavia's earnings in 2025 is -$24,549,000.On average, 2 Wall Street analysts forecast MTVA's earnings for 2025 to be -$20,444,604, with the lowest MTVA earnings forecast at -$26,998,615, and the highest MTVA earnings forecast at -$13,890,592. On average, 2 Wall Street analysts forecast MTVA's earnings for 2026 to be -$14,184,055, with the lowest MTVA earnings forecast at -$21,911,920, and the highest MTVA earnings forecast at -$6,456,191.
In 2027, MTVA is forecast to generate -$19,955,498 in earnings, with the lowest earnings forecast at -$19,955,498 and the highest earnings forecast at -$19,955,498.